Predicting Factors of Plasma HIV RNA Undetectability after Switching to Co-Formulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Experienced HIV-1 Patients: A Multicenter Study

Predicting Factors of Plasma HIV RNA Undetectability after Switching to Co-Formulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Experienced HIV-1 Patients: A Multicenter Study

Switching to bictegravir, emtricitabine, and tenofovir alafenamide (BIC/FTC/TAF) from other antiretroviral regimens is safe and effective for virologically suppressed people living with HIV (PLWH). The term virological suppression includes both low but detectable HIV viremia and undetectable HIV vir...

Повний опис

Бібліографічні деталі
Автори: Monica Basso, Giuliana Battagin, Stefano Nicolè, Maria Cristina Rossi, Francesco Colombo, Nicole Pirola, Stefano Baratti, Silvia Storato, Federico Giovagnorio, Vincenzo Malagnino, Grazia Alessio, Antonio Vinci, Massimo Maurici, Loredana Sarmati, Saverio Giuseppe Parisi
Формат: Стаття
Мова:English
Опубліковано: MDPI AG 2023-08-01
Серія:Viruses
Предмети:
co-formulated bictegravir
emtricitabine and tenofovir alafenamide
experienced HIV-1-positive patients
HIV RNA undetectability
HIV RNA control prior to switch
CD4+ nadir
Онлайн доступ:https://www.mdpi.com/1999-4915/15/8/1727

Інтернет

https://www.mdpi.com/1999-4915/15/8/1727

Схожі ресурси